Fulcrum Therapeutics Inc
NASDAQ:FULC
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.16
12
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Fulcrum Therapeutics Inc
Wall Street
Price Targets
FULC Price Targets Summary
Fulcrum Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
FULC
is 5.39 USD
with a low forecast of 2.02 USD and a high forecast of 14.7 USD.
FULC Last Price Targets
Fulcrum Therapeutics Inc
The latest public price target was made on Sep 13, 2024 by
Andrew Fein
from
H.C. Wainwright
,
who expects
FULC
stock to
rise by 19%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Andrew Fein
H.C. Wainwright
|
4
USD
Upside 19% |
2 months ago
Sep 13, 2024
|
Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TheFly
|
Gregory Renza
RBC Capital
|
4
USD
Upside 19% |
2 months ago
Sep 12, 2024
|
Fulcrum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
TheFly
|
Tazeen Ahmad
Bank of America Securities
|
2
USD
Downside 40% |
2 months ago
Sep 12, 2024
|
BofA Securities Downgrades Fulcrum Therapeutics (FULC) to Underperform
StreetInsider
|
Dae Gon Ha downgraded Fulcrum Therapeutics
Stifel Nicolaus
|
3
USD
Downside 11% |
2 months ago
Sep 12, 2024
|
Fulcrum Therapeutics downgraded to Hold from Buy at Stifel
TheFly
|
|
Tazeen Ahmad
Bank of America Securities
|
10
USD
Upside 198% |
2 months ago
Sep 9, 2024
|
BofA Securities Upgrades Fulcrum Therapeutics (FULC) to Neutral
StreetInsider
|
|
Gregory Renza
RBC Capital
|
15
USD
Upside 346% |
2 months ago
Sep 3, 2024
|
Fulcrum Therapeutics (FULC) PT Raised to $15 at RBC Capital
StreetInsider
|
|
Kristen Kluska
Cantor Fitzgerald
|
23
USD
Upside 585% |
5 months ago
May 20, 2024
|
Cantor Fitzgerald Starts Fulcrum Therapeutics (FULC) at Overweight
StreetInsider
|
|
Dae Gon Ha
Stifel Nicolaus
|
22
USD
Upside 555% |
6 months ago
May 13, 2024
|
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
StreetInsider
|
Corinne Jenkins
Goldman Sachs
|
15
USD
Upside 346% |
6 months ago
May 13, 2024
|
Goldman Sachs Upgrades Fulcrum Therapeutics (FULC) to Buy
StreetInsider
|
|
Gregory Renza
RBC Capital
|
14
USD
Upside 317% |
8 months ago
Mar 13, 2024
|
RBC Capital Starts Fulcrum Therapeutics (FULC) at Outperform, 'A Rare Disease Pipeline with Its DUX in a Row'
StreetInsider
|
| Price Target | 3 USD |
| Upside/Downside | 11% |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is FULC's stock price target?
Price Target
5.39
USD
According to Wall Street analysts, the average 1-year price target for
FULC
is 5.39 USD
with a low forecast of 2.02 USD and a high forecast of 14.7 USD.
What is Fulcrum Therapeutics Inc's Revenue forecast?
Projected CAGR
171%
The
compound annual growth rate
of Fulcrum Therapeutics Inc's revenue for the next 3 years is
171%.
You don't have any saved screeners yet
